The Delta coronavirus variant, with a dramatic transmission advantage over the Alpha variant that emerged in the UK, threatens global plans for dispatching COVID-19, 

A documentary released in March by Robert F.

The pandemic set back the fight against polio, but a new $5.1 billion plan launched today by

The UN agreed yesterday on ambitious new goals for ending the AIDS pandemic by 2030—despite eleventh hour attempts by some delegates to water down protections for high-risk groups,

“I think everyone who wants it has already gotten it,” a health worker was told, holding a cooler of soon-to-expire COVID-19 vaccines doses. All went unused.    

A new Alzheimer’s drug has secured FDA approval for the first time in nearly 2 decades, and not everyone is happy about it.   Biogen’s new drug, Aduhelm, is expensive ($56,000 per year) and highly controversial:

When COVID-19 hit, some med students were given the option to graduate early to join the fight.   Knowing that their entry into the profession would be less comfort and healing and more war zone, they nicknamed their cohorts “Coalition Forces” and “Covid Army.”

Can a universal coronavirus jab help us avoid another nail-biting wait for vaccines during the next pandemic? Lessons learned about coronavirus vaccine technology during this pandemic already offer a head start—and early research has shown some promise.  

COVID-19 cases are trending upward in 14 African countries and have shot up by more than 30% in 8 countries—as the continent awaits vaccine shipments.  

Yet another COVID-19 shot, known as a protein subunit vaccine, could hit the market as early as this summer,